ONKURE THERAPEUTICS
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solid tumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with ot... her targeted therapies. OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.
ONKURE THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Therapeutics
Founded:
2011-01-01
Address:
Boulder, Colorado, United States
Country:
United States
Website Url:
http://www.onkuretherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
720-307-2892
Email Addresses:
[email protected]
Total Funding:
67.49 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Immusoft
Immusoft, a biotechnology company, commercializes technologies that program the human immune system by modifying the DNA in related cells.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Tyra Biosciences
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
Surveyor Capital
Surveyor Capital investment in Series B - OnKure Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - OnKure Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - OnKure Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - OnKure Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Series B - OnKure Therapeutics
Delian Capital
Delian Capital investment in Series A - OnKure Therapeutics
OnKure management
OnKure management investment in Series A - OnKure Therapeutics
Key Employee Changes
Official Site Inspections
http://www.onkuretherapeutics.com Semrush global rank: 4.37 M Semrush visits lastest month: 2.58 K
- Host name: wpx.net
- IP address: 194.1.147.46
- Location: Chicago United States
- Latitude: 41.8719
- Longitude: -87.6589
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60607
More informations about "OnKure Therapeutics"
OnKure Therapeutics - About Our Company
Jul 14, 2021 OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer that are underserved by available therapies.See details»
OnKure Therapeutics Leadership Team
Aug 12, 2021 At Pfizer Boulder and the legacy Array BioPharma organization, Dr. Wong oversaw nonclinical and translational in vivo studies to support the small molecule oncology โฆSee details»
OnKure Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 720-307-2892 OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs.See details»
OnKure Therapeutics - LinkedIn
Investors.onkuretherapeutics.com 189 14 Comments Like Comment Share OnKure Therapeutics 2,866 followers 8mo Report this post We're excited to announce that OnKure has welcomed Sam Agresta, M.D., M ...See details»
Contacts, Employees, Board Members, Advisors & Alumni
General Counsel and Senior Vice President Corporate Affairs. Non-Management, Executive Legal. 1 email found 1 phone number foundSee details»
Corporate Governance - OnKure Therapeutics
Investor Contact. Dan Ferry LifeSci Advisors. drafts [email protected]. phone_iphone 617-430-7576See details»
OnKure Therapeutics - PitchBook
OnKure Therapeutics General Information Description. OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated โฆSee details»
OnKure Expands Executive Team with the Addition of โฆ
Aug 3, 2021 At Array BioPharma, Dr. Winkler served as Vice President of Biology, leading a discovery and early development organization with an impressive record of accomplishment, placing over 16 drugs into ...See details»
OnKure Announces the Appointment of Dylan Hartley, Ph.D. as โฆ
BOULDER, CO, July 25, 2024 โ OnKure, Inc. today announced that Dylan Hartley, Ph.D. has been appointed to the position of Chief Scientific Officer. In this position, Dr. Hartley will lead โฆSee details»
OnKure Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial โฆSee details»
OnKure, Inc. Raises $55 Million Series B Financing
Mar 4, 2021 For more information about OnKure, please visit www.onkuretherapeutics.com. Contacts. Investor Contact: Solebury Trout John Graziano Tel: +1 646-378-2942 Email: โฆSee details»
OnKure Company Profile - Office Locations, Competitors, Revenue โฆ
OnKure $8.09 m in total funding,. See insights on OnKure including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
OnKure Therapeutics Appoints Jason Leverone, CPA, as Chief
BOULDER, Colo., Feb. 08, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation...See details»
OnKure Expands Executive Team with the Addition of Chief โฆ
BOULDER, ColoradoโAugust 3, 2021 โ OnKure, Inc., a clinical-stage biopharmaceutical company pioneering a novel Class-1 selective histone deacetylase inhibitor for the treatment โฆSee details»
OnKure Therapeutics Announces $54 Million Series C
BOULDER, Colorado, May 23, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc. a precision oncology company, today announced that it has successfully closed a $54 million Series C financing.See details»
Release Details - investors.onkuretherapeutics.com
4 days ago Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT. BOULDER, Colo., Nov. 25, 2024 (GLOBE โฆSee details»
OnKure Therapeutics Announces Positive Topline First-in-Human โฆ
Dec 14, 2021 For more information, please visit www.onkuretherapeutics.com and follow us on LinkedIn and Twitter. Contacts. Media: Julia Deutsch Solebury Trout โฆSee details»
OnKure Therapeutics - Our Success is Written in Our DNA
The OnKure team is comprised of proven drug discovery and development scientists who are combining their cancer biology, medicinal chemistry and development expertise to create a โฆSee details»
OnKure Therapeutics Clinical Pipeline
OKI-219 is being investigated in the PIKture-01 clinical trial. PIKture-01 is a First-in-Human Study of the PI3Kฮฑ H1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants with โฆSee details»